David Hymel - Publications

Affiliations: 
2008-2014 Medicinal Chemistry University of Kansas, Lawrence, KS, United States 
 2014- Novo Nordisk 

19 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Mehrotra S, Lam S, Glenn E, Hymel D, Sanford CA, Liu Q, Herich J, Wulff BS, Meek TH. Unanticipated Characteristics of a Selective, Potent Neuromedin-U Receptor 2 Agonist. Acs Bio & Med Chem Au. 2: 370-375. PMID 37102164 DOI: 10.1021/acsbiomedchemau.2c00016  0.309
2022 Tsuji K, Hymel D, Ma B, Tamamura H, Nussinov R, Burke TR. Development of ultra-high affinity bivalent ligands targeting the polo-like kinase 1. Rsc Chemical Biology. 3: 1111-1120. PMID 36128509 DOI: 10.1039/d2cb00153e  0.347
2021 Hymel D, Tsuji K, Grant RA, Chingle RM, Kunciw DL, Yaffe MB, Burke TR. Design and synthesis of a new orthogonally protected glutamic acid analog and its use in the preparation of high affinity polo-like kinase 1 polo-box domain - binding peptide macrocycles. Organic & Biomolecular Chemistry. PMID 34346472 DOI: 10.1039/d1ob01120k  0.366
2020 Tsuji K, Hymel D, Burke TR. A new genre of fluorescence recovery assay to evaluate polo-like kinase 1 ATP-competitive inhibitors. Analytical Methods : Advancing Methods and Applications. 12: 4418-4421. PMID 32970049 DOI: 10.1039/D0Ay01223H  0.302
2020 Qi J, Tsuji K, Hymel D, Burke TR, Hudecek M, Rader C, Peng H. Chemically programmable and switchable CAR-T therapy. Angewandte Chemie (International Ed. in English). PMID 32329959 DOI: 10.1002/Anie.202005432  0.456
2019 Qi J, Hymel D, Nelson CG, Burke TR, Rader C. Conventional and Chemically Programmed Asymmetric Bispecific Antibodies Targeting Folate Receptor 1. Frontiers in Immunology. 10: 1994. PMID 31497024 DOI: 10.3389/Fimmu.2019.01994  0.353
2019 Knewtson KE, Perera C, Hymel D, Gao Z, Lee MM, Peterson BR. Antibody-Drug Conjugate that Exhibits Synergistic Cytotoxicity with an Endosome-Disruptive Peptide. Acs Omega. 4: 12955-12968. PMID 31460422 DOI: 10.1021/acsomega.9b01585  0.373
2019 Zhao XZ, Tsuji K, Hymel D, Burke TR. Development of Highly Selective 1,2,3-Triazole-containing Peptidic Polo-like Kinase 1 Polo-box Domain-binding Inhibitors. Molecules (Basel, Switzerland). 24. PMID 31014020 DOI: 10.3390/Molecules24081488  0.453
2018 Hymel D, Grant RA, Tsuji K, Yaffe MB, Burke TR. Histidine N(τ)-cyclized macrocycles as a new genre of polo-like kinase 1 polo-box domain-binding inhibitors. Bioorganic & Medicinal Chemistry Letters. PMID 30174151 DOI: 10.1016/J.Bmcl.2018.08.018  0.428
2017 Nanna AR, Li X, Walseng E, Pedzisa L, Goydel RS, Hymel D, Burke TR, Roush WR, Rader C. Harnessing a catalytic lysine residue for the one-step preparation of homogeneous antibody-drug conjugates. Nature Communications. 8: 1112. PMID 29062027 DOI: 10.1038/S41467-017-01257-1  0.412
2017 Park JE, Hymel D, Burke TR, Lee KS. Current progress and future perspectives in the development of anti-polo-like kinase 1 therapeutic agents. F1000research. 6: 1024. PMID 28721210 DOI: 10.12688/F1000Research.11398.1  0.359
2017 Lu X, Nowicka U, Sridharan V, Liu F, Randles L, Hymel D, Dyba M, Tarasov SG, Tarasova NI, Zhao XZ, Hamazaki J, Murata S, Burke TR, Walters KJ. Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets. Nature Communications. 8: 15540. PMID 28598414 DOI: 10.1038/Ncomms15540  0.304
2017 Li X, Nelson CG, Nair RR, Hazlehurst L, Moroni T, Martinez-Acedo P, Nanna AR, Hymel D, Burke TR, Rader C. Stable and Potent Selenomab-Drug Conjugates. Cell Chemical Biology. PMID 28330604 DOI: 10.1016/J.Chembiol.2017.02.012  0.416
2017 Zhao XZ, Hymel D, Burke TR. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides. Bioorganic & Medicinal Chemistry. PMID 28285924 DOI: 10.1016/J.Bmc.2017.02.063  0.363
2016 Hymel D, Burke T. Phosphatase-stable Phosphoamino Acid Mimetics that Enhance Binding Affinities with the Polo-Box Domain of Polo-like Kinase 1. Chemmedchem. PMID 27992122 DOI: 10.1002/Cmdc.201600574  0.422
2016 Zhao XZ, Hymel D, Burke TR. Application of oxime-diversification to optimize ligand interactions within a cryptic pocket of the polo-like kinase 1 polo-box domain. Bioorganic & Medicinal Chemistry Letters. PMID 27624074 DOI: 10.1016/J.Bmcl.2016.08.098  0.382
2015 Hymel D, Cai S, Sun Q, Henkhaus RS, Perera C, Peterson BR. Fluorescent mimics of cholesterol that rapidly bind surfaces of living mammalian cells. Chemical Communications (Cambridge, England). PMID 26287483 DOI: 10.1039/C5Cc06325F  0.645
2014 Hymel D, Woydziak ZR, Peterson BR. Detection of protein-protein interactions by proximity-driven S(N)Ar reactions of lysine-linked fluorophores. Journal of the American Chemical Society. 136: 5241-4. PMID 24660775 DOI: 10.1021/Ja501253B  0.547
2012 Hymel D, Peterson BR. Synthetic cell surface receptors for delivery of therapeutics and probes. Advanced Drug Delivery Reviews. 64: 797-810. PMID 22401875 DOI: 10.1016/J.Addr.2012.02.007  0.643
Show low-probability matches.